Metronidazole cream 0.75%
- Drugs List
- Therapeutic Indications
- Precautions and Warnings
- Pregnancy and Lactation
- Side Effects
Cream containing metronidazole.
Treatment of rosacea
1 application twice a day. Duration of treatment varies according to brand but should not exceed 4 months.
Children aged 1 to 18 years (unlicensed)
1 application twice a day.
Children under 1 year
Precautions and Warnings
Children aged 1 to 18 years
Central nervous system disorder
History of haematological disorder
Severe hepatic impairment
Some formulations contain propylene glycol
Avoid contact with mucous membranes
Avoid use in or near eyes
If accidental contact with the eyes occurs, rinse thoroughly with water
Marked skin irritation - interrupt treatment/reduce application frequency
Advise patient to avoid alcohol during treatment
Advise pt. to minimise exposure to sunlight & avoid sunlamps during therapy
Pregnancy and Lactation
Use metronidazole cream with caution during pregnancy.
One manufacturer advises that metronidazole cream is contraindicated during the first trimester of pregnancy. However, another manufacturer advises that this medication should only be used in pregnancy if clearly needed. At the time of writing there is limited human data available. With oral administration, metronidazole crosses the placental barrier and enters the foetal circulation. Some studies have indicated an increased risk of malformations and carcinogenic risk but these have not been clarified.
Metronidazole cream is contraindicated during breastfeeding.
The manufacturer advises discontinuing breastfeeding or discontinuing metronidazole. Metronidazole is excreted into human breast milk. Up to 100% of the plasma value can be reached after oral use. In topical application of metronidazole, these plasma levels are lower.
Burning sensation (local)
Worsening of rosacea
It is strongly recommended that the UK National Poisons Information Service be consulted on cases of suspected or actual overdose where there is doubt over the degree of risk or about appropriate management.
The following number will direct the caller to the relevant local centre (0844) 892 0111
Information may be obtained if you have access to ToxBase the primary clinical toxicology database of the National Poisons Information Service. This is available via password on the internet ( www.toxbase.org ) or if this is unavailable at the backup site ( www.toxbasebackup.org ).
Last Full Review Date: December 2019
Summary of Product Characteristics: Rozex 0.75% w/w cream. Galderma (U.K.) Ltd. Revised August 2013.
Summary of Product Characteristics: Rosiced 7.5mg/g cream. Pierre Fabre Dermatologie. Revised March 2015.
Already a member? Log in
Medscape UK | Univadis prescription drug monographs & interactions are based on FDB Multilex Content
FDB Disclaimer : FDB Multilex is intended for the use of healthcare professionals and is provided on the basis that the healthcare professionals will retain FULL and SOLE responsibility for deciding what treatment to prescribe or dispense for any particular patient or circumstance.